AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02431494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination of BLP and Microcurrent
Description: Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
Study NCT02329262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring to be Active with Accelerometers
Description: Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
Study NCT02329262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Planning to be Active with Accelerometers
Description: Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
Study NCT03117296 — intervention group
Intervention type: OTHER
Intervention: Post procedure daily PT and OT
Description: PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
Study NCT03117296 — intervention group
Intervention type: OTHER
Intervention: PT post procedure
Description: post procedure day one: PT and OT assessment, education and intervention.
Study NCT03117296 — intervention group
Intervention type: OTHER
Intervention: OT post procedure
Description: PT and OT Daily until goals met or patient discharge.
Study NCT03117296 — intervention group
Intervention type: OTHER
Intervention: Routine PT or OT
Description: Routine PT or OT consulted by physician when identified discharge disposition of home
Study NCT01044485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lapatinib
Description: escalation dose from 1250 to 1500 mg in association with docetaxel
Study NCT01044485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
Study NCT03305263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: One tablet a day from inclusion until end of pregnancy or gestational age 28
Study NCT03305263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine placebo
Description: One tablet a day from inclusion until end of pregnancy or gestational age 28
Study NCT04094103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active strawberry powder
Description: Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.
Study NCT04094103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo strawberry powder
Description: Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.
Study NCT04094103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed strawberry powder
Description: Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
Study NCT00053963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT04609917 — intervention group
Intervention type: PROCEDURE
Intervention: trainee invlovement
Description: Patients underwent selective biliary cannulation with trainee involvement
Study NCT02149992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol
Description: myo-inositol, oral, 2g, twice a day for 5 days total
Study NCT00898807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: target dose 30mg daily for 9 weeks
Study NCT00898807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily for 9 weeks
Study NCT02149992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring surveillance
Description: monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
Study NCT02149992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose monitoring
Description: patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
Study NCT00213239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
Study NCT00213239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
Study NCT02601144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation
Study NCT02601144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation
Study NCT02974244 — intervention group
Intervention type: DRUG
Intervention: exenatide once weekly
Description: exenatide treatment in the customary clinical care in the USA
Study NCT02974244 — intervention group
Intervention type: DRUG
Intervention: basal insulin
Description: basal insulin treatment in the customary clinical care in USA
Study NCT02103842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Study NCT01548235 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
Study NCT04067999 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
Study NCT01461551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
Study NCT01461551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
Study NCT01461551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combine of sevoflurane and propofol
Description: anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
Study NCT00733434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Description: PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
Study NCT00733434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
Study NCT04472689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
Study NCT04472689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
Study NCT03815175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE
Description: Subjects who received XIENCE family stent systems will be included.
Study NCT03815175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT (aspirin and/or P2Y12 receptor inhibitor)
Description: 1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up.
Study NCT00866437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin test panel
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study NCT03797729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
Study NCT03797729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Informed Consent
Description: To be completed prior to conducting any study related procedures
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Written Informed Consent
Description: To be completed prior to conducting any study related procedures
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion/Exclusion check
Description: Eligibility check
Study NCT00866437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin test panel
Description: Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study NCT00779168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: white button mushroom extract
Description: For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inclusion/Exclusion check
Description: Eligibility check
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Clinical Chemistry and Haematology Bloods
Description: Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Full Clinical Chemistry and Haematology Bloods
Description: Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum sample for systemic markers and lipid sub-fractions
Description: Serum samples may be stored for later analysis.
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum sample for systemic markers and lipid sub-fractions
Description: Serum samples may be stored for later analysis.
Study NCT02688023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
Description: The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
Study NCT01559428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched margarine
Description: Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
Study NCT00779168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
Study NCT01559428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol-enriched margarine
Description: Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
Study NCT01559428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control margarine
Description: Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
Study NCT00779168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
Study NCT00779168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
Study NCT00779168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas chromatography-mass spectrometry
Description: Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
Study NCT00779168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnancy Test
Description: If applicable for women of child bearing potential
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pregnancy Test
Description: If applicable for women of child bearing potential
Study NCT03840291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban will be used for resolution of left atrial appendage thrombi
Study NCT00834067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
Description: 1 x 15/25 mg
Study NCT00834067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UNIRETIC® 15/25 mg tablets
Description: 1 x 15/25 mg
Study NCT00426621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel
Description: 4 grams per knee, 4 times per day, for 12 weeks
Study NCT00426621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 grams per knee, 4 times per day, for 12 weeks
Study NCT01250912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-metaiodobenzylguanidine
Description: FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
Study NCT03801980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1403
Description: Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
Study NCT03801980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
Study NCT01116362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary repair
Description: during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
Study NCT01116362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary repair
Description: after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
Study NCT03359356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: A total of 24 doses
Study NCT03359356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 24 doses
Study NCT03491579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
Study NCT03491579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Standard chemotherapy
Study NCT03491579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Standard chemotherapy
Study NCT00836758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analysis with AED and manual PSG scoring
Description: The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
Study NCT01093963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: oral; 20-70mg/day
Study NCT01093963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral; 20-70mg/day
Study NCT03792477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).
Study NCT03792477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).
Study NCT03655535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTI320
Description: Non-systemic galactomannan complex polysaccharide
Study NCT03655535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00495222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue plication
Description: Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
Study NCT00495222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Suturing System
Description: Tissue plication of dilated GJ stoma
Study NCT00495222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Plication
Description: Tissue plication for GJ stoma reduction
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 Lead ECG
Description: participant resting supine
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 12 Lead ECG
Description: participant resting supine
Study NCT04685486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
Study NCT00834405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA® 20 mg tablets
Description: 1 x 20 mg, single-dose non-fasting
Study NCT00834405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg Tablets
Description: 1 x 20 mg, single-dose non-fasting